Supply and delivery of pharmaceutical specialties. Consultation initiated by a group of orders composed of the following members:

- list of available members in the RC,

- order group coordinator: GCS Epsilimforme de marché: with purchase orders without minimum or maximum. Award of a framework agreement for each lot. Framework agreement concluded for an initial period of 8 months, from 1.5.2019 to 31.12.2019. Estimated amount of benefits for the duration of the framework agreement: EUR 1 582 200.

B01ab - LMWH for curative treatment, 2 daily injections.

G03aa10 - gestodene + ethinyl estradiol.

J01cr02 - amoxicillin + injectable clavulanic acid.

J01dh02 - meropenem

J01xx09 - daptomycin

L01ba01 - methotrexate solution ready to use, without preservative.

L01bc02 - fluorouracile ready-to-use solution.

L01xc03 - trastuzumab.

L04ab04 - adalimumab.

V03ae02 - sequelamer.

Melatonin.

B01ab - LMWH for preventive treatment.

B01ab01 - calcium heparin.

B01ad - thrombolytics for venous catheter uncoupling.

B05ba02 - lipid emulsion at 20%.

C07ab02 - metoprolol.

C08ca05 - nifedipine.

C08ca05 - nifedipine lP.

G03aa10 - gestodene + ethinyl estradiol.